A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic Non Small Cell Lung Cancer (Stage IIIB- IV)

Inclusion Criteria:

- Locally advanced or metastatic non small cell lung cancer (IIIB-IV)

- Failure of first line anti-cancer therapy (either radiological documentation of
disease progression or due to toxicity) in advanced disease or subsequent relapse of
disease following first line therapy

- Tumour sample confirmed as KRAS mutation positive (Note: Sample must be available
upon enrolment to ship to AZ appointed central laboratory, or mutation status
confirmed locally at AstraZeneca agreed local laboratory using agreed methodology, or
mutation status confirmed by an accredited (eg CLIA certified) commercial laboratory
(eg Genzyme or Lab 21).

Exclusion Criteria:

- Received >1 prior anti-cancer therapy for advanced or metastatic non small cell lung
cancer (excluding radiotherapy)

- Prior treatment with a MEK inhibitor or any docetaxel containing regimen (prior
treatment with paclitaxel is acceptable)

- Having received an investigational drug within 30 days of starting treatment, or have
not recovered from side effects of an investigational drug

- Brain metastases or spinal cord compression unless asymptomatic, treated and stable
off steroids and anti-convulsants for at least 1 month